The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

Tiffany Foo; David Goldstein; Eva Segelov; Jeremy Shapiro; Nick Pavlakis; Jayesh Desai; Desmond Yip; John Zalcberg; Timothy J. Price; Adnan Nagrial; Lorraine Chantrill; Matt Burge; Christos S. Karapetis; Niall Tebbutt; Amitesh C. Roy

doi:10.1007/s11523-022-00869-y

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

Tiffany Foo, David Goldstein, Eva Segelov, Jeremy Shapiro, Nick Pavlakis, Jayesh Desai, Desmond Yip, John Zalcberg, Timothy J. Price, Adnan Nagrial, Lorraine Chantrill, Matt Burge, Christos S. Karapetis, Niall Tebbutt, Amitesh C. Roy

College of Medicine and Public Health

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

137 Downloads (Pure)

Abstract

Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.

Original language	English
Pages (from-to)	95-110
Number of pages	16
Journal	Targeted Oncology
Volume	17
Issue number	2
Early online date	15 Mar 2022
DOIs	https://doi.org/10.1007/s11523-022-00869-y
Publication status	Published - Mar 2022

Keywords

Gastrointestinal stromal tumours
Tyrosine kinase inhibitors
Patient outcomes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11523-022-00869-yLicence: CC BY-NC

s11523-022-00869-yFinal published version, 902 KBLicence: CC BY-NC

Cite this

@article{765769117d3348c7aecfdf002128b8b0,

title = "The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours",

abstract = "Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.",

keywords = "Gastrointestinal stromal tumours, Tyrosine kinase inhibitors, Patient outcomes",

author = "Tiffany Foo and David Goldstein and Eva Segelov and Jeremy Shapiro and Nick Pavlakis and Jayesh Desai and Desmond Yip and John Zalcberg and Price, {Timothy J.} and Adnan Nagrial and Lorraine Chantrill and Matt Burge and Karapetis, {Christos S.} and Niall Tebbutt and Roy, {Amitesh C.}",

year = "2022",

month = mar,

doi = "10.1007/s11523-022-00869-y",

language = "English",

volume = "17",

pages = "95--110",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "2",

}

TY - JOUR

T1 - The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

AU - Foo, Tiffany

AU - Goldstein, David

AU - Segelov, Eva

AU - Shapiro, Jeremy

AU - Pavlakis, Nick

AU - Desai, Jayesh

AU - Yip, Desmond

AU - Zalcberg, John

AU - Price, Timothy J.

AU - Nagrial, Adnan

AU - Chantrill, Lorraine

AU - Burge, Matt

AU - Karapetis, Christos S.

AU - Tebbutt, Niall

AU - Roy, Amitesh C.

PY - 2022/3

Y1 - 2022/3

N2 - Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.

AB - Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.

KW - Gastrointestinal stromal tumours

KW - Tyrosine kinase inhibitors

KW - Patient outcomes

UR - http://www.scopus.com/inward/record.url?scp=85126280231&partnerID=8YFLogxK

U2 - 10.1007/s11523-022-00869-y

DO - 10.1007/s11523-022-00869-y

M3 - Review article

C2 - 35290591

AN - SCOPUS:85126280231

SN - 1776-2596

VL - 17

SP - 95

EP - 110

JO - Targeted Oncology

JF - Targeted Oncology

IS - 2

ER -

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this